Strokes kill 45% more women than men in Canada, according to a new data analysis released by the Heart and Stroke Foundation. And that?s why Canadian women have a strong reason to be aware of the warning signs of stroke, says the Foundation.
A study of more than 33,000 type 2 diabetes patients in a real-world setting was published today. This study shows that the incidence of hospitaliations for heart attack, and/or for a surgery known as coronary revascularization for patients on Avandia is the same as for other diabetes treatments.
Andrew Speaker learned Monday evening that his third consecutive sputum smear test had come back negative. This confirmed results from several smear tests previously performed at other institutions.
Researchers at Cedars-Sinai Medical Center announced today the start of the EASE (Exhale Airway Stents for Emphysema) Trial, an international, multi-center clinical trial to explore an investigational treatment that may offer a new, minimally-invasive option for those suffering with advanced widespread emphysema.
Mutations in the cell adhesion molecule known as integrin alpha 7 (integrin ?7) lead to unchecked tumor cell proliferation and a significantly higher incidence in cancer spread, or metastasis, in several cancer cell lines, report researchers at the University of Pittsburgh School of Medicine in a study being published today in the Journal of the National Cancer Institute.
In a special publication sent to thousands of oncologists nationwide this month, University of Rochester Medical Center scientists offer an in-depth examination of cancer-related fatigue, with hope that a better understanding of the topic will prompt new research and treatment.
The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), today released its NIAID Research Agenda for Multidrug-Resistant (MDR) and Extensively Drug-Resistant (XDR) Tuberculosis (TB).
Low levels of testosterone may increase the long-term risk of death in men over 50 years old, according to researchers with the Department of Family and Preventive Medicine at the University of California, San Diego School of Medicine.
GlaxoSmithKline [NYSE:GSK] said that findings from an interim analysis of RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycemia in Diabetes), a prospective clinical trial designed specifically to determine cardiovascular outcomes in more than 4,400 patients with type 2 diabetes, adds further evidence to the overall cardiovascular safety profile of Avandia? (rosiglitazone maleate).
The following is GlaxoSmithKline?s [NYSE:GSK] response to editorials written in the New England Journal of Medicine (NEJM) regarding Avandia? for the treatment of type 2 diabetes.